Organization
Candel Therapeutics
10 clinical trials
1 abstract
Clinical trial
Neoadjuvant CAN-2409 Plus Prodrug in Combination With Chemoradiation or Stereotactic Body Radiation Therapy for Borderline Resectable Pancreatic AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Phase IIa Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant GliomasStatus: Completed, Estimated PCD: 2015-12-01
Clinical trial
Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate CancerStatus: , Estimated PCD: 2024-12-01
Clinical trial
AdV-tk + Valacyclovir Therapy in Combination With Surgery and Chemoradiation for Pancreas CancerStatus: Completed, Estimated PCD: 2013-05-01
Clinical trial
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain TumorsStatus: Completed, Estimated PCD: 2015-12-01
Clinical trial
A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural EffusionStatus: Completed, Estimated PCD: 2015-12-01
Clinical trial
A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant GliomasStatus: Completed, Estimated PCD: 2010-01-01
Clinical trial
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC PatientsStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Abstract
CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.Org: University of Pennsylvania, NYU Langone Medical Center, Vanderbilt University Medical Center, University of Chicago, Division of Pulmonary and Critical Medicine, Department of Medicine, Mayo Clinic,